Urothelial Tract Neoplasm - Urothelial Tract/Bladder Cancer
NCT02177695
Clinical Trial Information
Trial Number: NCT02177695 (ClinicalTrials.gov)
Disease Type:
- Urothelial Tract Neoplasm - Urothelial Tract/Bladder Cancer
Trial Title:
"A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer"
Study ID:
S1314
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT02177695-D1 | This dataset contains participant-level data (one row per participant), including treatment, demographic, and baseline information. It also contains assessment data, including data needed for time-to-event analyses. The unique participant identifier in this dataset is the same identifier used in the S1314 molecular dataset found in the Gene Expression Omnibus database (record ID: GSE244266). |
NCT00942331
Clinical Trial Information
Trial Number: NCT00942331 (ClinicalTrials.gov)
Disease Type:
- Urothelial Tract Neoplasm - Urothelial Tract/Bladder Cancer
Trial Title:
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
Study ID:
CALGB-90601
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00942331-D3 | Dataset NCT00942331-D3-Dataset.csv (ae_all) is one of 3 datasets associated with PubMed ID 33989025. This dataset contains adverse event information. |
| NCT00942331-D2 | Dataset NCT00942331-D2-Dataset.csv (dosemod_all) is one of 3 datasets associated with PubMed ID 33989025. This dataset contains dose modification reasons for all patients with at least one dose reduction or delay. There is also a variable distinguishing the dose modification between cisplatin and gemcitabine. |
| NCT00942331-D1 | Dataset NCT00942331-D1-Dataset.csv (pt_all) is one of 3 datasets associated with PubMed ID 33989025. This dataset contains all patient level data including baseline characteristics, survival status and time to event, progression free survival and time to event, treatment summaries, off treatment reasons for chemotherapy and bev/placebo, best response, tumor scans, the occurrence of grade 3/4 thrombocytopenia, the occurrence of a serious adverse event, and the occurrence of a dose delay or reduction. |
NCT00445601
Clinical Trial Information
Trial Number: NCT00445601 (ClinicalTrials.gov)
Disease Type:
- Urothelial Tract Neoplasm - Urothelial Tract/Bladder Cancer
Trial Title:
A Phase III Blinded Study of Immediate Post TURBT Instillation of Gemcitabine Versus Saline in Patients With Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer
Study ID:
S0337
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00445601-D2 | This dataset will allow users to reproduce the toxicity results reported in the Journal of American Medical Association (Messing et al., JAMA, 2018, PMID referenced above) for trial NCT00445601. |
| NCT00445601-D1 | This dataset will allow users to reproduce the patient-level efficacy results reported in the Journal of American Medical Association (Messing et al., JAMA, 2018, PMID referenced above) for trial NCT00445601. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®